Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma

Leukemia Research

Volumn 35, Issue 11, 2011, Pages

  Carter, Stephanie J ^a   Bernstein, Steven H ^a   Friedberg, Jonathan W ^a   Barr, Paul M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CLINDAMYCIN; COTRIMOXAZOLE; INFUSION FLUID; PARACETAMOL; PREDNISONE; PRIMAQUINE; RITUXIMAB;

AGED; ANEMIA; ARTHRALGIA; BLOOD CULTURE; CANCER CHEMOTHERAPY; CASE REPORT; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRY COUGH; DYSPNEA; ELBOW DISEASE; FEVER; FIBEROPTIC BRONCHOSCOPY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; HYPOXIA; KNEE PAIN; LETTER; LUNG LAVAGE; MALE; MARGINAL ZONE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NODULAR HYPERPLASIA; OXYGEN SUPPLY; PHYSICAL EXAMINATION; PLEURA THICKENING; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RIGOR; SYMPTOMATOLOGY; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TACHYPNEA; TROPHOZOITE; URINE CULTURE; WEAKNESS; WRIST DISEASE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; NITROGEN MUSTARD COMPOUNDS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; TREATMENT OUTCOME;

EID: 80053937873     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.07.014     Document Type: Letter

References (10)

1. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2009 114: Abstract 405.
2. Rummel MJ, Kaiser U, Balser C, et al. Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab In Patients with Relapsed Follicular, Indolent and Mantle Cell Lymphomas - Final Results of the Randomized Phase III Study NHL 2-2003 on Behalf of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 856.
3. Byrd J.C., Hargis J.B., Kester K.E., et al. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995, 49:135-142.
4. Friedberg J.W., Cohen P., Chen L., et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 2008, 26:204-210.
5. Ohmachi K., Ando K., Ogura M., et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010, 101:2059-2064.
6. Kahl B.S., Bartlett N.L., Leonard J.P., et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010, 116:106-114.
7. Robinson K.S., Williams M.E., van der Jagt R.H., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-4479.
8. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
9. Klippstein A., Schneider C.P., Sayer H.G., et al. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol 2003, 129:316-319.
10. Cheson B.D., Wendtner C.M., Pieper A., et al. Optimal use of bendamustine in chronic lymphocytic leukemia non-Hodgkin lymphomas, and multiple myeloma: treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 2010, 10:21-27.